ADRB2 and neoplasm: Among the β2AR inhibitors, Propranolol, an FDA approved Pan-Beta blocker has been shown to improve outcomes of radiation (21), Immune checkpoint inhibitors (ICI) (22–24) & chemotherapies (25) in pre-clinical tumor models.